JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of JNJ-63733657 in Healthy Chinese Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-06-07
Last Posted Date
2023-12-11
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
10
Registration Number
NCT05407818
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

First Posted Date
2022-06-02
Last Posted Date
2023-09-15
Lead Sponsor
Janssen Research & Development, LLC
Registration Number
NCT05401214
Locations
🇲🇽

DUMMY, Dummy, Mexico

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

First Posted Date
2022-05-24
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
418
Registration Number
NCT05388669
Locations
🇺🇸

City of Hope Duarte, Duarte, California, United States

🇵🇹

Ulsm - Hosp. Pedro Hispano, Senhora da Hora, Portugal

🇺🇸

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States

and more 184 locations

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

First Posted Date
2022-05-24
Last Posted Date
2023-10-12
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
60
Registration Number
NCT05387759
Locations
🇧🇪

Clinical Pharmacology Unit, Merksem, Belgium

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

First Posted Date
2022-05-18
Last Posted Date
2024-12-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
225
Registration Number
NCT05379595
Locations
🇺🇸

O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

University of California, Los Angeles UCLA, Los Angeles, California, United States

and more 50 locations

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-05-18
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
36
Registration Number
NCT05379634
Locations
🇺🇸

University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, United States

🇺🇸

Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States

🇺🇸

The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States

and more 54 locations

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-05-06
Last Posted Date
2024-12-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
227
Registration Number
NCT05364554
Locations
🇯🇵

Shizuoka General Hospital, Shizuoka, Japan

🇬🇧

Guys and St Thomas NHS Foundation Trust, London, United Kingdom

🇺🇸

Pacific Skin Institute, Sacramento, California, United States

and more 56 locations

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-05-03
Last Posted Date
2024-12-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
90
Registration Number
NCT05357755
Locations
🇺🇸

Dermatology Specialists, Louisville, Kentucky, United States

🇺🇸

Unity Clinical Research, Oklahoma City, Oklahoma, United States

🇩🇪

Privatpraxis Dr. Hilton & Partner, Dusseldorf, Germany

and more 30 locations

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

First Posted Date
2022-04-21
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
74
Registration Number
NCT05338775
Locations
🇺🇸

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath